On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.
Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...
Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...
Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.
Automated insulin delivery (AID) systems reduce diabetes distress and fear of hypoglycemia, improve quality of life, and increase awareness about hypoglycemia in adults, children, and adolescents ...
The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...
Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...
Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...
Reports Q3 revenue $543.9M, consensus $518.26M. “We continue to achieve significant milestones and robust revenue growth,” said Jim ...
From wearable glucose monitors to AI-driven health insights, recent advances are giving patients new ways to manage blood ...
SAN DIEGO, CA / ACCESSWIRE / October 23, 2024 / Luna Diabetes announces the start of its pivotal trial for the Luna System today. Luna is the first automated insulin delivery solution intended for ...
CNW/ - Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. This approval represents an important step ...